Home › Compare › URANF vs ABBV
URANF yields 13698.63% · ABBV yields 3.06%● Live data
📍 URANF pulled ahead of the other in Year 1
Combined, URANF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of URANF + ABBV for your $10,000?
International Prospect Ventures Ltd., a junior mineral exploration company, engages in the evaluation, exploration, and promotion of mineral properties in Canada. The company explores for gold, uranium, and other mineral deposits. It holds 100% interest in the Porcupine Miracle prospect, which consists of four mineral tenements located in Langmuir Township, Ontario; and the Otish/Mistassini prospect, which comprises 46 mining claims covering an area of 2,447 hectares located in the North Central Québec. It also holds 100% interest in the Beartooth Island Prospect, which comprises one mining claim covering an area of 22,581 hectares located in the northwest portion of the Athabaska Basin, Saskatchewan; and the Elliot Lake uranium property situated in Ontario, Canada. The company was formerly known as Uranium Valley Mines Ltd. and changed its name to International Prospect Ventures Ltd. in October 2017. International Prospect Ventures Ltd. was incorporated in 2010 and is headquartered in Val-d'Or, Canada.
Full URANF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.